Archeologists find ancient child remains inside Maya altar
The painting and artistry is not what sticks out to archeologists at a newly discovered ancient altar in Guatemala. The likely sacrificed human remains and its craftsmanship tells the story of a major conflict between a Maya city-state and a powerful rival. The findings are detailed in a study published April 8 in the journal Antiquity.
Archaeologists believe that the altar was built around the late 300s CE in the Maya city of Tikal. It is decorated with four panels painted red, black, and yellow and depict a person wearing a feathered headdress near regalia and shields. The face itself looks a bit like other depictions of a Maya deity called the 'Storm God,' with somewhat almond-shaped eyes, a nose bar, and a double earspool.
The team believes that it was created by an unknown highly skilled artisan who was trained in Teotihuacan. This formidable ancient power was centered about 630 miles west of Tikal, outside present-day Mexico City.
'It's increasingly clear that this was an extraordinary period of turbulence at Tikal,' Stephen Houston, a study co-author and archaeologist at Brown University, said in a statement. 'What the altar confirms is that wealthy leaders from Teotihuacan came to Tikal and created replicas of ritual facilities that would have existed in their home city. It shows Teotihuacan left a heavy imprint there.'
Established around 850 BCE, Tikal initially existed as a small city with little influence in the area. Around 100 CE, the city became a larger and more powerful dynasty. Temples from this large city-state still stand in the jungle and its residents battled with the Kaanul dynasty for dominance of the greater Maya world.
Teotihuacan, 'the city of the gods' or 'the place where men become gods,' was home to the Temples of the Sun and Moon. Over 100,000 people lived within its roughly eight square miles and it was one of the largest cities in the world at its peak between 100 BCE and 750 CE. Ultimately, Teotihuacan was mysteriously abandoned before the Aztecs rose during the 14th century.
Archaeologists have some evidence that Tikal and Teotihuacan began regularly interacting around 650 BCE. According to Houston, what first appeared to be casual trading quickly became more strained.
'It's almost as if Tikal poked the beast and got too much attention from Teotihuacan,' Houston said. 'That's when foreigners started moving into the area.'
[ Related: Ancient Maya masons had a smart way to make plaster stronger. ]
In the 1960s, archaeologists found a cut stone with well-preserved text describing the conflict between the two cities in broad terms. The stone's text revealed that Teotihuacan was 'essentially decapitating a kingdom,' around 378 CE. 'They removed the king and replaced him with a quisling, a puppet king who proved a useful local instrument to Teotihuacan,' said Houston.
Several years later, light detection and ranging (LiDAR) technology, revealed a scaled-down replica of the Teotihuacan citadel located just outside the center of Tikal. Archeologists believe that it was buried under natural hills and suggest that Teotihuacan's presence in the city likely involved an element of occupation or surveillance in the years before its overthrow.
The altar in this new study was built right around the time of the coup. The team believes that the altar's meticulously painted exterior represents only a fraction of the evidence for the capital's major presence. Archaeologists found a child buried in a seated position inside of the altar. While both cities did practice human sacrifice, this specific burial practice was rare in Tikal but common at Teotihuacan.
Remains of other children were also found on three sides of the altar. Lorena Paiz, the archaeologist who led the discovery, believes that it was likely used for human sacrifice, particularly children. 'The remains of three children not older than 4 years were found on three sides of the altar,' Paiz told The Associated Press.
An adult with a dart point made out of green obsidian was also found inside of the altar. The material and the design of the dart are also distinct to Teotihuacan and not Tikal.
The fact that the altar and the area around it was later buried indicate that Teotihuacan's presence changed and scarred Tikal.
'The Maya regularly buried buildings and rebuilt on top of them,' study co-author and archeologist Andrew Scherer said in a statement. 'But here, they buried the altar and surrounding buildings and just left them, even though this would have been prime real estate centuries later. They treated it almost like a memorial or a radioactive zone. It probably speaks to the complicated feelings they had about Teotihuacan.'
[ Related: Ancient Mayan human sacrifices involved twins. ]
Archeologists believe that Tikal's collective memory of this Teotihuacan coup was likely pretty complicated. While it may have rocked Tikal, the takeover ultimately made the kingdom more powerful. Throughout the next several centuries, Tikal became a nearly unmatched dynasty. It ultimately declined around 900 CE with the rest of the Maya world.
'There's a kind of nostalgia about that time, when Teotihuacan was at the height of its power and taking increasing interest in the Maya,' Houston said. 'It's something exalted for them; they looked back on it almost wistfully. Even when they were in decline, they were still thinking about local politics in context of that contact with central Mexico.'
One striking detail about this ancient story is how it is one that has been played out across the world. A mighty empire plunders the riches of another smaller city.
'Everyone knows what happened to the Aztec civilization after the Spanish arrived,' Houston said. 'Our findings show evidence that that's a tale as old as time. These powers of central Mexico reached into the Maya world because they saw it as a place of extraordinary wealth, of special feathers from tropical birds, jade and chocolate. As far as Teotihuacan was concerned, it was the land of milk and honey.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Enslaved Africans led a decade-long rebellion 1,200 years ago in Iraq, new evidence suggests
When you buy through links on our articles, Future and its syndication partners may earn a commission. Around 1,200 years ago in what is now Iraq, enslaved people who were forced to build a vast canal system defied authority and rebelled, a new study indicates. Between A.D. 869 to 883 a group known as the Zanj, many of whom were enslaved people taken from Africa, rebelled against the Abbasid Caliphate (ruled from 750 to 1258) and disrupted its control over the region, according to historical texts. The records also suggest that during the Middle Ages, the Zanj helped build a large system of canals spanning nearly 310 square miles (800 square kilometers) that was used to irrigate agriculture near the city of Basra. These canals are no longer used, but their earthen remains, including 7,000 human-made ridges, are still visible across the landscape. While researchers have long known about the canal system, no one had ever dated the ridges to see if they were constructed during the ninth-century Zanj rebellion. To investigate, the researchers collected and dated soil samples from within four of the ridges in an effort to learn more about who built them. Using optically stimulated luminescence (OSL) dating, a technique that estimates when soil was last exposed to sunlight, the team determined that the ridges were built sometime between the late ninth to mid-thirteenth centuries A.D., they reported in their study published June 2 in the journal Antiquity. "The close dating between some of the ridges and the time of the rebellion makes it very likely that people who were involved in the rebellion were involved in the creation of some of these features," study first author Peter J. Brown, an archaeologist at the Radboud Institute for Culture and History in the Netherlands and Durham University in the U.K., told Live Science in an email. The results also indicate that construction of the ridges continued long after the rebellion ended. "We have a more limited understanding of exactly what happened afterwards and whether large numbers of slaves continued to work across this field system or whether 'free' local peasant farmers took over," Brown said. The fact that the work on the ridges came to an end during the mid-thirteenth century could be related to the Mongol invasion of the region, which resulted in the sack of Baghdad in 1258, the authors wrote in their paper. The ninth-century revolt was not the Zanj's first rebellion. They also revolted in 689 to 690 and 694 to 695, according to historical texts. However, both of these insurrections were quickly suppressed. In contrast, the third revolt ended up "sparking more than a decade of unrest until the Abbasid state regained control of the region," according to the study. Life as an enslaved person digging canals was brutal, and medieval texts provide some clues as to what life was like for the Zanj. Before the rebellion, the textual sources describe work camps distributed throughout the canal region, with groups of 50 to 500 enslaved people in each camp, Brown said. "They seem to have been in a servile situation with 'agents' or 'masters' who were in charge of them, and the historical sources suggest they were treated poorly but we don't have details about the conditions in which they lived," Brown said. The labor they had to perform was backbreaking. "The workers who built this system would have had to dig out the canals and pile up earth into the large ridge features we can see on the ground today, " Brown said, noting that the slaves may have used animals such as donkeys to help with transporting sediment. After the canals were built, they needed to be cleaned frequently "to keep them functional as water carries silt that would be deposited within the canal beds," Brown said. "Over time, [the silt] would lead to them becoming unusable if they were not routinely cleaned." RELATED STORIES —14 wrecks that expose 'what life was like on slaver ships' identified in the Bahamas —Origins of enslaved Africans freed by British, then abandoned on remote Atlantic island revealed by DNA analysis —Plantation slavery was invented on this tiny African island, according to archaeologists Adam Ali, an assistant professor of Arabic language at the University of Toronto who has a doctorate in Islamic history, said that the study is interesting but cautioned that the samples come from just four of the ridges and more work is needed to verify the study findings. "I think that this study opens an avenue for further the discussion and examination of these ridges and what they can tell us," Ali, who was not involved in the research, told Live Science in an email. The possibility that slaves from Africa kept being used on the canals after the rebellion is important, Kristina Richardson, a professor of Middle Eastern and South Asian languages and cultures and history at the University of Virginia, told Live Science in an email. "The findings are extraordinary and surprising, because they upend the historical consensus that Middle Easterners stopped using East Africans as agricultural slaves after the suppression of the Zanj Rebellion in 883."


Medscape
16 hours ago
- Medscape
Teamwork in Oncology Spotlighted at ASCO
This transcript has been edited for clarity. Mark A. Lewis, MD: Hello. I'm Dr Mark Lewis, director of Gastrointestinal Oncology at Intermountain Health in Utah. Joining me today is Dr Stephanie Graff, director of the Breast Oncology Program at Brown University Health's Cancer Institute, and co-leader of the Breast Cancer Translational Research Disease Group. Today, we would like to talk to you about the latest updates from the 2025 ASCO Annual Meeting. Stephanie, it's a true joy to sit down with you. I always look forward to ASCO. I sometimes explain to my patients that it's like the Super Bowl of oncology, and I don't think that's hyperbolic. It's the largest meeting of the year. One of the true advantages is getting to network with people like you, but also — I don't know about you — I get a real tangible sense of progress, and I often tell my patients, 'Listen, I'm going to go to this meeting. I don't want to over-promise and underdeliver, but I think there's a real chance that I'll bring back something new that might affect your care.' There are the big four tumor types in oncology, breast, lung, [gastro intestinal (GI), and genitourinary]. You practice above the diaphragm, and I practice below the diaphragm. As we might talk about in the Venn diagram, I think we overlap. I'm just curious what's exciting you at this meeting? Stephanie L. Graff, MD: In breast oncology, there's been a large amount of really exciting news. One of the ASCO plenary sessions, which we haven't heard yet, is SERENA-6, which will be looking at camizestrant with circulating tumor DNA (ctDNA). That'll be exciting. We're getting updates on overall survival with the INAVO120 regimen. We saw this morning that it improved survival, which is great. We also are going to be seeing data looking at trastuzumab deruxtecan in HER2-positive breast cancer in the first line and then other data looking at targeted therapies for things like PI3 kinase. Our first oral [abstract] PROTAC, Dr Hamilton presented today, also showed improvement in progression-free survival. Many things like that are exciting and certainly starting to change practice. Pembrolizumab and sacituzumab [are] changing practice in first-line metastatic triple-negative breast cancer. There's so much and it's a really great breast oncology ASCO. Lewis: I'm so glad to hear that. There are a couple areas I think that we definitely overlap. I'm curious to get your thoughts on ctDNA. My sense as a GI oncologist is that it is a very prognostic biomarker, but it is not always demonstrably predictive. My real reservation in using it, to be honest with you, is: Number one, I don't think it entirely supplants our traditional clinical pathologic understanding. For instance, as a GI oncologist, if I think someone has high-risk stage III colon cancer and their initial postoperative ctDNA is negative, I'm not entirely going to abandon my approach to their adjuvant therapy. Also thinking about it as a patient, we're sometimes telling these people that they have literal subclinical disease. You can make the argument, 'Well, why wait until cells aggregate to the point that you can see them as an actual tumor on a scan?' On the other hand, I worry sometimes about the psychological impact of ctDNA. As you said, we'll hear about SERENA-6 tomorrow. I think that's a really interesting study in the sense of letting patients be aware of emerging ESR1 mutations that are conferring resistance to aromatase inhibition. I'll be really curious to see the outcome of that study and whether that's a meaningful change for the patient, because I think we sometimes actually underestimate the psychological weight. Graff: It's interesting. In breast oncology, we've benefited from a wealth of patient advocacy, driving a wealth of progress, funding, and advancing science, which has been really beneficial in our field. We actually have done research looking at how the psychological impact affects how patients handle disease. I think that, historically, you can imagine a time in medicine when people thought, 'Oh, those sweet little girls, we shouldn't weigh them down with the worry about cancer.' That has borne out to not be true. When we think about telling people the results of a mammogram that needs additional imaging or biopsy, or that they have dense breast tissue or that their mammogram needs additional follow-up in 6 months, none of those things actually increase or decrease a patient's worry. Lewis: Interesting. Graff: What helps is just open and honest communication. I think what's more important is that we empower physicians and oncologists with the tools to actually understand what these tests mean and how to communicate effectively with patients about them. I think patients are going to be worrying about the fact that they have cancer. Good test or bad test, that patient knows the next test might not be the same. Good test or bad test, their cancer could have a different outcome down the roadway. They're going to worry. I don't have cancer and I worry. I worry about my kids. I worry about my house. I worry about the weather. We all worry. I think that just having the tools to explain what's going on is probably the most powerful thing that we can do. Lewis: That is such a wonderful anecdote to literal and figurative paternalism, and you're absolutely right. We already have these points of apprehension in patient care and diagnostics, and I think ctDNA potentially adds to that, but we can use the same methods of counseling that we've used for all these other tools. That's so well said. I also wanted to tell you — and I really, really mean this — that I view breast medical oncology as aspirational for the rest of solid tumor oncology. When you were mentioning trastuzumab deruxtecan earlier, one of my most vivid memories from ASCO meetings of any year was the plenary session where DESTINY-Breast04 was presented. I remember being part of the standing ovation for that trial, even though I don't treat breast cancer anymore, because I thought, 'Wow, we are really making progress in biomarker-driven care.' The other reason I view you as aspirational is we are not yet at that standard in GI oncology, at least, where it's a foregone conclusion that we would know all the biomarkers that we need to know. One of the interesting conversations I have with patients now is on pathologists as our silent, or at least unseen, partners. I think you would agree that you would almost never treat a patient with metastatic disease without knowing ER, PR, and HER2 status. Meanwhile, over in GI oncology, I'm sometimes having to ask for these things to be done that would be relevant to my patients, say KRAS mutations or BRAF mutations. To me, it seems like it should be as reflexive for me as it is for you as a breast cancer oncologist. What I'm getting at here, too, is this is back to how we have conversations with patients. I think patients need to understand, again, that biomarkers are a huge part of how we personalize their care, even though they might never actually meet their pathologists. Again, I just wanted to tell you, because I don't often get to sit with you, that the way that breast cancer oncologists — and to your own point, patient advocates — have kind of pushed things forward, it's a rising tide that lifts all boats. I often use your field as an example of where we should be. Graff: It's ironic because I have maybe the opposite perspective. As a breast oncologist, I feel like, here we are in 2025 with all these amazing genomic ctDNA and RNA assays, and we're still using ER, PR, and HER2, which is — spoiler alert — literally dumping ink on slides, right? It's immunohistochemistry. Our thoracic oncology colleagues are using true genomic-driven care to look at ROS1 , EGFR , and all these different things to say, based on this profile, this is what you're going to get. We're like, well, we have to wait for that ER to come back. I'm a little bit jealous that some fields have more genomic-driven care than breast does, but you're right. Breast was definitely a pioneer in biomarkers. DESTINY-Breast04 is an interesting example because, if anything, it shows that the biomarker doesn't matter, right? Trastuzumab deruxtecan is a HER2 antibody, and as it turns out, it works great for HER2-positive disease, but it also works great for HER2 not-so-positive disease. DESTINY-Breast06 now includes ultra-low, which is zero with just a little bit of fuzzy in the background. We're seeing that maybe we're not getting our biomarkers right after all. Lewis: So well said. I remember thinking about the effect in ultra-low and thinking, man, how strong is this bystander effect? If the chemo payload is being delivered to barely present HER2 receptors, it must be really potent indeed. I often think that we're actually putting a large amount of credence in what our pathologists tell us. For instance, like you said, immunohistochemistry is very qualitative, sort of semi-quantitative. Again, with things like PD-L1, it's funny how we all have sour grapes to other tumor types. Thinking about continuous variables, we can always debate the appropriate cutoff. Pathologists have actually warned us at this very meeting. I remember Anirban Maitra standing up and saying, 'Listen, you guys need to realize, as pathologists, the number that we give you for PD-L1 expression, for instance, that's our impression on that day, on that slide. You really shouldn't take it to be gospel truth.' Again, I think we're still finding our way with that. Graff: We've seen, in breast oncology, a presentation at this meeting looking at if that's the forefront for AI, right? Is that where artificial intelligence is going to be able to augment our ability, because again, we heard in the opening session that AI should be a tool that is an agent to advance human skills. If AI can help augment the eye of the pathologist, enhance the skills of the microscope, and move HER2 zero to HER2 ultra-low with more accuracy than the naked eye or more robustly in global centers where access to those stains aren't as readily available, then AI is advancing care for everyone equitably around the globe: the same global population that's participating in these trials and bringing them to our patient population. Back to biomarker-driven care, I think it just comes back down to patient communication. All of these tests take time. Even in breast oncology, sometimes my patients have to wait. They have to wait for ESR1 . It's a mechanism of resistance. I don't have it until their disease progresses and I can send that test out. That means that sometimes they have to have some patience while we wait and make sure that they're a candidate for the right therapy at the right time. That requires partnership with a bunch of people on my team. The staff that draw the blood and the mail room staff that ship it out to the right team. I'm so thankful that I have a huge wealth of people that make the cancer center work. Lewis: So well said. I often tell my patients that oncology is a team sport. Graff: Yes. Lewis: I think the last thing I wanted to say is that you and I have talked a little bit about the pace of progress as a wonderful problem to have. I'm curious, [going] off your comment about sort of global equity, how do you feel like that plays out in sort of clinical trial design? Graff: The breast oncology community discussed this today as some data were revealed. An interesting problem that we're starting to have in breast cancer is the rapidity of new agents relative to the rapidity of trial accrual. This means that, if it takes a year to design a trial and get regulatory approval, and then another year to accrue and then another year to read out results, by then there have been 27 new drugs added, right? I think we had 25 regulatory approvals last year in the US, or something like that, in oncology. Whatever the standard-of-care control arm was in the study 3 years ago when that trial was designed is laughable. I'm going to use the example of second-line HR-positive breast cancer. We have two problems. Problem number one is that the standard control arm is fulvestrant. When many of these trials were accruing in 2020 and 2021, that was the standard of care. Now, we have ESR1-targeting agents. We have PI3 kinase-targeting agents. We have data that extending a CDK4/6 inhibitor is efficacious. We have evidence for earlier trastuzumab deruxtecan for patients that maybe aren't so endocrine sensitive. We can always extend everolimus into that space. There's all this other stuff, including oral SERDs. There are so many different directions we can go. I don't even remember what all I've listed [to] at this point. We're getting the next generation of medicine, but they're still being compared to fulvestrant. Lewis: Right. Graff: We're looking at these results, saying, 'Well, great, you beat that drug we used back in the late 1900s.' Lewis: Right. Yes. Graff: Now, I think that another problem is that global angle, which is that not all of those new drugs, although almost all of these trials are global trials, they're accruing these from international countries. Not all of the regulatory agencies have approved them internationally. Not all of the payers have approved them internationally because they meet different benchmarks around the globe. Lewis: Yes. Graff: That standard-of-care arm isn't available as we advance. Again, trial design gets complicated because if we want the control arm to be the US standard of care, and that's different than the German standard of care, the Indian standard of care, the Kenyan standard of care, or the Argentinian standard of care; then we have to make sure that they're connected with that standard of care. We have to make sure that they're comfortable delivering that standard of care and figure out what that really looks like. Lewis: I think where I completely agree with you is you have to walk before you can run. It's really exciting to see the sophisticated assays like ctDNA, but I'm sitting here thinking, based on your comments, I can't even guarantee that I'll have mismatch repair protein status in my patients with colon cancer. Again, we have to take this in a stepwise fashion. You're right that, for all the excitement that we understandably and should feel at meetings like this, we do have to temper our enthusiasm a little bit and be practical in the real world. I have to say, Stephanie, it's just a delight to sit with you. I think you really are a true exemplar of shared decision making. Again, it really, at the end of the day, doesn't come down to the primary site. Yes, you're a breast oncologist. Yes, I'm a GI oncologist. A rising tide lifts all boats, and I think, as we also heard this morning, there's a difference between irrational exuberance and unjustified optimism, and then there's legitimate hope. At least what I feel at these meetings, and I strongly suspect you do too, is legitimate hope for our patients. Graff: I agree. Lewis: With that, we'll close. Again, thank you for joining us. We hope this was a helpful summary of what we've been hearing today at the ASCO 2025 Annual Meeting. Thank you.


Indianapolis Star
18 hours ago
- Indianapolis Star
Archeologists discover 2,500-year-old Midas dynasty tomb in Turkey
A 2,500-year-old royal tomb has been discovered by archeologists at the site of an ancient city in Turkey. After four months of excavations, Penn Museum and Ankara Hacı Bayram Veli University archeologists discovered a well-preserved royal tomb chamber that dates back to 8th century BCE (800 to 701 BCE). The tomb's roof was collapsed, but objects inside remained intact, including bronze vessels used during banquets, iron rods, a pair of large bronze cauldrons and assorted smaller bronze cauldrons, jugs and bowls, according to a news release. The tomb was discovered at the archeological site of Gordion, the capital of the Phrygian kingdom, which controlled much of Asia Minor during the first millennium BCE, Gordion Excavation Director C. Brian Rose said in a news release. Gordion is located in northwest Turkey, about 60 miles southwest of Turkey's capital Ankara. At one time, Gordion was ruled by King Midas, famously known for his "golden touch." Archeologists believe that the newly-discovered tomb may have belonged to a member of the Midas dynasty. Iron Age archaeological find: British 'bling' from 2,000 years ago included horse harnesses Archeologists used magnetic prospection technology to find the tomb, a news release states. This geophysical method uses variations in Earth's magnetic field to identify objects below the surface, according to the U.S. Environmental Protection Agency. To archeologists' surprise, the tomb indicated a cremated burial. Up until this latest excavation, researchers believed the first cremation to occur in Gordion was more than 100 years later. Vessels inside the tomb also featured textiles adhered to their exterior, which indicate that textiles were an important industry in Gordion, Rose said in a news release. 3,000-year-old Mayan city unearthed: Why it's named 'The Grandparents' The tomb was located near and appeared like the Midas Mound tomb, which is believed to have housed the body of King Midas' father. The Gordion site has proved fruitful for archeologists for 75 years, since Penn Museum began leading excavations there in 1950. Previous excavations included the oldest wooden building in the world, dating back to 740 BCE. Others include the earliest colored stone mosaics found in Gordion, the best-preserved citadel gate of the first millennium and a gilded ivory sphinx of the 6th century BCE, according to a news release.